Description
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 3
Primary Industries
- Drugs
- Diagnostic
- Disease
- Therapeutic
- Respiratory
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 203289
The technology is Zileuton XR, the extended-release tablet formulation of Zileuton as described in Licensors NDA filed thereon; and Zileuton IR,(the product), the immediate-release tablet formulation of Zileuton marketed as ZVFLO®, zileuton tablets, as described in the supplemental NDA relating thereto filed by Licensor. Zileuton means the racemic compound 00-1-(1-benzo[b]thien-2-ylethyl)-1-hydroxyurea.
Zileuton is an orally active inhibitor of 5-lipoxygenase, and thus inhibits leukotrienes (LTB4, LTC4, LTD4, and LTE4) formation, used for the maintenance treatment of asthma.
IPSCIO Record ID: 203507
Licensor grants, subject to third partys written consent, an exclusive sublicense under Licensors rights to Patents and Know How pursuant to the License Agreement to develop, have developed, make, have made, use, have used, import, have imported, offer to sell, sell, and have sold Zileuton CR in the Field in the Territory.
The Compound is Zileuton. Zileuton CR is the controlled release formulation of the Compound. Zileuton IV is the intravenous formulation of the Compound. The Excluded Product is the finished form of the Compound currently marketed under the trade name of Zyflo.
Zileuton (trade name ZYFLO) is an orally active inhibitor of 5-lipoxygenase, and thus inhibits leukotrienes (LTB4, LTC4, LTD4, and LTE4) formation, used for the maintenance treatment of asthma.
'Indication' shall mean a distinct disease or condition in the Field for which Regulatory Approval has been sought and/or obtained, including, without limitation, all forms of the following diseases or conditions asthma, chronic obstructive pulmonary disease, and emphysema.
IPSCIO Record ID: 203372
Licensor irrevocably and unconditionally sells, transfers, conveys, assigns and delivers, and Licensee hereby purchases all right, title and interest in and to the Trademark and the goodwill.
The Product is any pharmaceutical product which incorporates Zyflo or an immediate release formulation of the compound Zileuton.
Zileuton (trade name ZYFLO) is an orally active inhibitor of 5-lipoxygenase, and thus inhibits leukotrienes (LTB4, LTC4, LTD4, and LTE4) formation, used for the maintenance treatment of asthma.
